1609235-63-3

Upstream product

• 1609235-68-8 2-(azidomethyl)-3,4-dihydro-2H-benzo[h]chromene 
• 1609235-67-7 (3,4-dihydro-2H-benzo[h]chromen-2-yl)methyl 4-methylbenzenesulfonate 
• 1609235-52-0 (3,4-dihydro-2H-benzo[h]chromen-2-yl)methanol 
• 711-79-5 1-hydroxy-2-acetonaphthone 
• 169747-40-4 ethyl 3,4-dihydro-2H-benzo[h]chromene-2-carboxylate 
• 92965-13-4 ethyl 4-oxo-4H-benzo[h]chromene-2-carboxylate 

Relevant academic research and scientific papers

Design and synthesis of 3,4-dihydro-2H-benzo[h]chromene derivatives as potential NF-κB inhibitors

A novel class of NF-κB inhibitors were designed and synthesized based on KL-1156 (6-hydroxy-7-methoxychroman-2-carboxylic acid phenyl amide) which is unambiguously considered to be a promising inhibitor for the translocation step of NF-κB. Especially in this study we focused on the modifying the chroman moiety of KL-1156 into four parts for exploring the SAR studies linked with physical properties of substituents resulted the development of novel 1a-k, 2a-f, 3a-d and 4a-d derivatives of 3,4-dihydro-2H-benzo[h]chromene. From the SAR studies we were very delightfully identified that several new N-aryl-3,4-dihydro-2H-benzo[h]chromene-2-carboxamide derivatives (1a-k) exhibited good inhibitory activity and anti-proliferative activity than parent lead compound KL-1156, among them 1i exhibited outstanding inhibitory effect on LPS-induced NF-κB transcriptional activity and anti-proliferative activity on NCI-H23 lung cancer cell lines than KL-1156.